文献速递心脑血管急症重症综合管理与镇静镇痛

肺动脉高压中完全植入式静脉曲前列尼尔治疗:植入程序评估

Totally Implantable IV Treprostinil Therapy in Pulmonary Hypertension Assessment of the Implantation Procedure.
PubMed 文献 · Chest · 2017-06-03
一句话结论多中心前瞻性单臂试验显示,60例肺动脉高压患者完全植入式静脉曲前列尼尔系统植入均成功,平均耗时102分钟,严重并发症少。

该多中心、前瞻性、单臂临床试验(DelIVery for PAH)纳入64例世界卫生组织第1组肺动脉高压患者,均在接受稳定静脉曲前列尼尔治疗。患者在手术前转换为临时外周静脉输注导管,随后在10个中心由不同专科医生在全身麻醉或深度静脉镇静下植入完全植入式静脉输注系统。60例植入手术全部成功,平均植入时间102±32分钟,临床显著并发症包括1例气胸、2例感染和1例心房颤动,另有2例患者发生3次导管移位。结论认为该植入手术成功率高、并发症少。

要点

  • 64例世界卫生组织第1组肺动脉高压患者中60例完成植入,所有60例手术均成功。
  • 基线时所有患者经外部泵接受曲前列尼尔,平均剂量71.4±27.8 ng/kg/min(范围22-142 ng/kg/min)。
  • 植入手术平均耗时102±32分钟(范围47-184分钟)。
  • 临床显著植入相关并发症:1例气胸、2例感染、1例心房颤动;2例患者发生3次植入后导管移位。
  • 常见非并发症植入相关事件:植入部位疼痛83%、瘀斑17%。

适用人群与场景

  • 世界卫生组织第1组肺动脉高压患者,正在接受稳定静脉曲前列尼尔治疗。
  • 入组患者N=64,其中4例在植入前退出,最终60例接受植入手术。

处置流程与药物剂量

  • 手术前将患者转换为临时外周静脉输注导管。
  • 在全身麻醉或深度静脉镇静下进行系统植入,由不同专科的临床医生操作。
  • 中心静脉通路可选择头静脉、锁骨下静脉、颈静脉或腋静脉。
  • 使用导引器和透视引导,将输注导管远端尖端置于上腔静脉-心房交界处。
  • 导管从静脉穿刺部位隧道化至腹部皮下囊袋,泵置于该囊袋内。

研究设计与关键结果

  • 研究类型:多中心、前瞻性、单臂临床试验(DelIVery for PAH),在10个中心进行。
  • 样本量:入组64例,4例在植入前退出,60例完成植入手术。
  • 干预:完全植入式静脉曲前列尼尔输注系统。
  • 主要结果:所有60例植入手术均成功;平均植入时间102±32分钟(范围47-184分钟)。
  • 并发症:临床显著植入相关并发症包括1例气胸、2例感染、1例心房颤动;2例患者发生3次植入后导管移位。
  • 非并发症植入相关事件:植入部位疼痛83%、瘀斑17%。
  • 基线曲前列尼尔剂量:平均71.4±27.8 ng/kg/min(范围22-142 ng/kg/min),经外部泵给药。

证据类型、等级与局限

  • 证据类型:多中心、前瞻性、单臂临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于正在接受稳定静脉曲前列尼尔治疗的世界卫生组织第1组肺动脉高压患者,完全植入式系统的植入手术可成功完成,并发症少(作者结论)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Prostacyclins improve symptoms and survival in pulmonary arterial hypertension (PAH). In response to risks associated with external delivery systems, an implantable IV infusion system was developed. A multicenter, prospective, single-arm, clinical trial (DelIVery for PAH) was conducted to evaluate this system for treprostinil in PAH. This analysis describes the findings related to the implant procedure.

METHODS: Patients (N = 64) with PAH (World Health Organization group 1) receiving stable IV treprostinil were enrolled. Patients were transitioned to a temporary peripheral IV infusion catheter prior to the procedure. System implantation was performed at 10 centers under general anesthesia or deep IV sedation by clinicians from various specialties. Central venous access was via the cephalic, subclavian, jugular, or axillary vein. Using an introducer and fluoroscopic guidance, the distal tip of the infusion catheter was placed at the superior caval-atrial junction. The catheter was tunneled from the venous access site to an abdominal subcutaneous pocket, where the pump was placed.

RESULTS: Of the 64 patients enrolled, four exited prior to implantation. All 60 implant procedures were successful. At baseline, all patients were receiving treprostinil via an external pump at a mean dose of 71.4 ± 27.8 ng/kg/min (range: 22-142 ng/kg/min). The implant averaged 102 ± 32 min (range: 47-184 min). Clinically significant implant procedure-related complications included one pneumothorax, two infections, and one episode of atrial fibrillation. There were three postimplantation catheter dislocations in two patients. Common implant-related events that were not complications included implant site pain (83%) and bruising (17%).

CONCLUSIONS: The procedure for inserting a fully implantable system for treprostinil was successfully performed, with few complications.

TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01321073; URL: www.clinicaltrials.gov.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Waxman AB, McElderry HT, Gomberg-Maitland M, et al. Totally Implantable IV Treprostinil Therapy in Pulmonary Hypertension Assessment of the Implantation Procedure. Chest. 2017. PMID: 28583617. doi:10.1016/j.chest.2017.04.188

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。